Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC26A6 | Q9BXS9 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775750 | 0.89 | SLC26A6 (0.46) | SLC26A6LMNATRPM8ALDH1A1NPC1 | |
| SCHEMBL2774616 | 0.89 | TARBP2 (0.50) | LMNATRPM8ALDH1A1NPC1RAB9A | |
| SCHEMBL2775657 | 0.89 | ADORA3 (0.48) | LMNAALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL2773774 | 0.88 | TARBP2 (0.51) | LMNAALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL2775078 | 0.87 | CACNA2D1 (0.41) | SLC26A6POLBTARBP2CACNA2D1HTT | |
| SCHEMBL2778512 | 0.86 | SLC26A6 (0.47) | SLC26A6LMNATRPM8ALDH1A1NPC1 | |
| SCHEMBL2773625 | 0.82 | SLC26A6 (0.44) | SLC26A6LMNATRPM8ALDH1A1NPC1 | |
| SCHEMBL2774268 | 0.81 | ALDH1A1 (0.47) | LMNATRPM8ALDH1A1NPC1RAB9A | |
| SCHEMBL2777192 | 0.80 | SLC26A6 (0.46) | SLC26A6LMNATRPM8ALDH1A1NPC1 | |
| SCHEMBL2775686 | 0.80 | EGLN1 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227475-B1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-8269008-B2 | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions | FIBROGEN, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2227475-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073669-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | HIF1AN, HIF1A, EGLN2 | SLC26A6 1970/4885LMNA 4078/4885TRPM8 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.